bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P5-13-20: Overall survival of women with breast cancer treated with newly approved targeted drugs in Manitoba: A population based study
Authors: Devgan S , Bucher O , Geirnaert M , Niraula S 
Published: May 2019

Abstract
Background: Cancer drugs are approved based on the results of clinical trials in selected, rigorously monitored groups of participants. The ultimate goal of new cancer drug approvals is to improve outcomes, preferably overall survival, at population level compared to existing standard of care.
Methods: We conducted a population based study using data from the provincial Manitoba cancer registry, Manitoba Health, and electronic patient records. We collected data on patient demographics, toxicity outcomes, and efficacy outcomes including recurrence and Overall Survival (OS) of patients who were treated with the 10 most frequently used new targeted cancer drugs between January 2005 and December 2017 in Manitoba. Patient demographics were reported using descriptive statistics. Toxicity events were reported in frequency, and Kaplan-Meier curves were used for time-to-event outcomes.
Results: Four breast cancer drugs – Trastuzumab Emtansine (T-DM1), pertuzumab, fulvestrant, and palbociclib qualified for inclusion. During the timeframe, 71 women were treated with T-DM1, 100 with pertuzumab, 102 with Fulvestrant, and 21 with palbociclib. Patient demographics, disease stage, and line of therapy were comparable to those reported in pivotal trials leading to approval of these drugs. Median OS was 15.82 months for T-DM1, 25.34 months for pertuzumab, 14.65 months for fulvestrant, and not assessable for palbociclib – of note, these were consistently about half the median OS duration reported in pivotal trials leading to approval of the respective drugs. [For example, median OS in pivotal trials was 55.6 months for pertuzumab, 29.9 months for T-DM1, up to 26.4 months for fulvestrant, and 37.5 months (one trial) for palbociclib]. Serious toxicities were observed more frequently than reported in the literature – detailed results will be presented.
Conclusion: Despite impressive improvements in outcomes reported in clinical trials leading to approval of new targeted therapies for breast cancer, such agents only yield modest OS at population level which was often worse than even the control groups used in pivotal clinical trials. Given the main aim of new interventions are to improve outcomes at population level, future research should explore causes, and identify solutions to minimize such efficacy-effectiveness gaps. Cautious patient selection, early identification and management of toxicities, and increasing resources available to individual patients may minimize such gaps.
Citation Format: Devgan S, Bucher O, Geirnaert M, Niraula S. Overall survival of women with breast cancer treated with newly approved targeted drugs in Manitoba: A population based study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-13-20.
Abstract P5-14-08: Not presented
Authors: Galindo-Vázquez O , Baragalló-Rocha E , Cabrera-Galeana P , Costas-Muñiz R , Lerma A , Esparza-Arias N 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Galindo-Vázquez O, Baragalló-Rocha E, Cabrera-Galeana P, Costas-Muñiz R, Lerma A, Esparza-Arias N. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-14-08.
Abstract P5-18-12: Effectiveness of Oncotype DX DCIS scoring in a community setting
Authors: Wheeler JA , Vaghefi H , Liu F , Owens V , Morris L , Denham F , Coody L 
Published: May 2019

Abstract
The Oncotype DX DCIS Score was developed to assist in determining a low risk for recurrence subgroup of patients who can avoid radiation therapy following breast conserving surgery. We sought to evaluate our experience using the Oncotype DX DCIS Score and to see if a greater number of patients who did not receive radiation therapy were experiencing a local recurrence than the score predicted.
Between February 23, 2011 and November 29, 2017, 145 women were diagnosed with ductal carcinoma in situ (DCIS) without an invasive component. 126 (87%) underwent breast conserving surgery. Thirty-five underwent Oncotype DX DCIS Score, of whom 26 (74%) were low risk, four were intermediate risk (11%), and five were high risk (14%).
The scores ranged from 0 (7 patients) to 100 (1 patient). Of the 26 patients with low risk scores, one chose to undergo mastectomy, three received radiation therapy, 20 chose observation without radiation therapy, and two patients were unknown because they had no further treatment or follow-up at our facility. Two of the four intermediate risk patients underwent radiation therapy and two did not. Four of the five high risk patients underwent radiation therapy, but one did not.
Twenty-two of the 35 patients who underwent Oncotype DX Score met the criteria for size (based on grade) and margins (at least 3 mm). Ten patients had margins that were less than 3 mm but met the size criteria. Two patients did not meet the size criteria but had at least 3 mm margins. One patient did not meet either the size or margin criteria. None of our 20 patients with low risk Oncotype DX DCIS Score and who met both the size and margin criteria recurred.
With the median follow-up of approximately 2-1/2 years, three of the 21 patients (14%) with low or intermediate risk scores who underwent Oncotype DX DCIS Score and did not receive radiation therapy suffered a local recurrence. The predicted average recurrence risk for these patients based on their Oncotype DX DCIS Score was 12%. Two of these patients who recurred had margins less than 3 mm, and one patient met the size and margin criteria, but had an intermediate risk score.
By comparison, five of 61 (8%) of patients who underwent breast conserving surgery and adjuvant radiation therapy had a local recurrence.
Twenty of the 23 (87%) low risk Oncotype DX DCIS Score patients did not receive radiation therapy and overall 20/35 (57%) of the patients undergoing Oncotype DX DCIS Score did not receive radiation therapy.
Although the follow-up is still relatively short, Oncotype DX DCIS Score allows a considerable number of women to avoid adjuvant radiation therapy.
Citation Format: Wheeler JA, Vaghefi H, Liu F, Owens V, Morris L, Denham F, Coody L. Effectiveness of Oncotype DX DCIS scoring in a community setting [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-18-12.
Abstract P6-01-05: Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles
Authors: Bischoff FZ , Mathieu K , Vargas J , Pang L , Kulp AM , Dewing A , Liu X , Bast RC , Hazle J , Zhang M 
Published: May 2019

Abstract
Background: Iron oxide nanoparticles (NPs) have been used for a variety of in-vivo and ex-vivo applications within the biomedical sciences. Moreover, when intended for clinical in-vivo applications, NPs need to meet rigorous requirements to ensure safety as well as bio-functionality including blood circulation time and specificity for cellular targets. PrecisonMRX® NPs are extensively characterized superparamagnetic NPs composed of a 25nm magnetite cores that are currently employed in a variety of in-vivo applications including non-invasive/in vivo diagnosis of cancer, Magnetic Particle Imaging, MRI, and magnetic hyperthermia.
Objective: Here we report on the extensive pre-clinical development and functionality of antibody (Herceptin)-conjugated NPs for in-vivo and ex-vivo detection of HER2+ tumor cells by Magnetic Relaxometry (MRX).
Results: We observed: 1) specific binding and detection of HER2 positive tumor cells in-vitro; 2) specific detection of HER2+ tumors in mice; 3) binding and amplitude of magnetic signal to be proportional to the level of HER2 expression in-vitro and in-vivo; 4) the nanoconstruct remains stable in circulation; 5) the particles do not induce a pro-inflammatory response nor activate complement; 6) the particles are biodegradable; and do not induce acute or delayed signs of morbidity in mice.
Conclusion: Precision MRX® nanoparticles offer great clinical promise including the in- vivo detection of tumor cells by magnetic relaxometry. Given the stability and safety of these NPs, our pre-clinical results support progressing to clinical testing. A first-in human ex-vivo clinical research study design and strategy will be discussed.
Citation Format: Bischoff FZ, Mathieu K, Vargas J, Pang L, Kulp AM, Dewing A, Liu X, Bast RC, Hazle J, Zhang M. Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-01-05.
Abstract P6-02-01: Not presented
Authors: Luo J , Chen Q , Tang L , Yang L , Han E , Chen Y , Yuan L 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Luo J, Chen Q, Tang L, Yang L, Han E, Chen Y, Yuan L. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-02-01.
Abstract P6-02-10: Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients
Authors: Adrada BE , Candelaria R , Moulder S , Lane D , Santiago L , Arribas E , Hess KR , Valero V , Thompson A , Helgason T , Ravenberg E , Yang W , Rauch GM 
Published: May 2019

Abstract
Background: Triple negative breast cancer (TNBC) is molecularly heterogeneous disease. Genomic profiling to identify the distinct TNBC subtypes is costly with long turnaround time. Early ultrasound after two cycles of neoadjuvant chemotherapy (NAC) has the potential to identify patients who are likely to have pathological complete response. Suspected non-responder patients can undergo comprehensive genetic testing and triaged for specific targeted therapeutic trials.
Aim: To determine the value of ultrasound evaluation after two cycles of NAC to predict complete pathologic response in TNBC breast cancer patients.
Methods: 98 patients enrolled in “A randomized triple Negative Breast Cancer Enrolling Trial to Confirm Molecular Profiling Improves Survival” (Artemis) at the University of Texas MD Anderson Cancer Center had ultrasound evaluation before treatment and after two cycles of NAC (Adriamycin and Cyclophosphamide). Three-dimensional measurements of the tumor were obtained at baseline and after 2 cycles of the NAC. Change in the tumor volume after 2 cycles of NAC was calculated. Residual cancer Volume (RCB) was calculated based on the final histopathology at surgery. Linear regression analysis evaluated associations between residual cancer burden (RCB) and change in volume of the index tumor.
Results: Median tumor size at diagnosis was 3 cm, range 0.6-11.9cm. Median size after two cycles was 2 cm, range 0.6-12.8 cm. RCB 0-I was seen in 55% of patients (54/98). Linear regression analysis demonstrated that of 22 patients with volume reduction &gt;75%, 18 patients (82%) had RCB0-I (95%CI, 61%-93%).
Conclusion: Our data suggest that ultrasound exam after 2 cycles of NAC can identify TNBC patients who are unlikely to respond to standard NAC. These non-responder TNBC patients can be triaged for additional genetic testing and subsequent targeted clinical trials. Study on the larger number of patients is currently on the way.
Citation Format: Adrada BE, Candelaria R, Moulder S, Lane D, Santiago L, Arribas E, Hess KR, Valero V, Thompson A, Helgason T, Ravenberg E, Yang W, Rauch GM. Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-02-10.
Abstract P6-02-18: Hepatic complications of breast cancer
Authors: Wong MJ , Choi H 
Published: May 2019

Abstract
Background
Breast cancer is the most common malignancy and the leading cause of cancer death in women in the United States. Nearly 30% of women with metastatic breast cancer will have liver metastases, with a median survival from time of 4.23 months from time of metastatic diagnosis. Hepatic involvement of breast cancer is common and can result from metastatic tumor burden or treatment with chemotherapy or radiation. Being able to recognize and diagnose hepatic involvement of breast cancer is of utmost importance, as it has a dramatic effect on patient prognosis and management.
Learning Objectives
To familiarize multidisciplinary clinical team members with the radiographic presentations of hepatic complications of breast cancer in a variety of imaging modalities including computed tomography, dual-energy computed tomography, ultrasound, and MR. This will facilitate accurate and prompt diagnosis and treatment of hepatic involvement of breast cancer.
Abstract
Our educational pictorial essay demonstrates the typical appearance of hepatic metastases on multiple imaging modalities, as well as atypical presentations such as hyperdense, hypervascular, or hypoechoic lesions and pseudoprogression. We will show examples of hepatic metastases presenting as pseudocirrhosis, left lobar atrophy, capsular retraction, as well as sequelae of pseudocirrhosis such as malignant ascites, varices, portal vein thrombosis, and biliary obstruction. We will discuss the radiographic appearance of the liver after being treated with locoregional liver-directed techniques such as surgical resection, ablation, and chemoembolization. Importantly, we will illustrate examples of hepatic complications from systemic therapy including steatohepatitis from tamoxifen, as well as hepatic fibrosis from gemcitabine.
Conclusion
Clinicians must have a thorough understanding of the hepatic complications of cancer to ensure excellent diagnostic accuracy and management.
References
1. Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer.Lancet Oncol. 2009;10:615–621.
2. Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, Robertson JF, Evans AJ, 2003 Prognostic factors for patients with hepatic metastases from breast cancer Brit J Cancer 89: 284–290.
3. Adike A, Karlin N, Menias C, Carey EJ. Pseudocirrhosis: A case series and literature review. Case Rep Gastroenterol. 2016;10(2):381–91
4. Agarwal K, Jones DE, Burt AD, et al. Metastatic breast carcinoma presenting as acute liver failure and portal hypertension. Gastroenterol Hepatol. 2002;97:750–751.
Citation Format: Wong MJ, Choi H. Hepatic complications of breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-02-18.
Abstract P6-05-08: LINC02273 interacts with hnRNPL and promotes metastasis through directly activating AGR2 in breast cancer
Authors: Xiu B , Chi Y , Ji W , Zhang Q , Wu J 
Published: May 2019

Abstract
The prognosis of breast cancer patients with metastasis is still poor even improved by current treatment modalities. Unveiling new biomarkers and molecular mechanisms that underlie metastasis are of vital importance for the treatment of breast cancer. The recent discovery of long noncoding RNAs (lncRNAs) has gained widespread attention. To identify critical lncRNAs that contributed to breast cancer metastasis, we profiled their expression in 5 pairs of primary tumors and lymph nodes metastasis loci by HTA2.0 microarray. LINC02273 is significantly upregulated in metastasis loci and its high expression is associated with poor diseases free survival in a validation set of 254 patients. LINC02273 was mainly located in the cell nucleus . RACE-PCR showed two isoforms and the longest one was the most abundant isoform in breast cancer. Through transwell assay, 3D spheroid invasion assay and mice xenograft metastasis model, we found that LINC02273 promoted breast cancer cell migration, invasion and metastasis. Via mass spectrometry, hnRNPL was found to interact with LINC02273 to enhance its stability, which was further confirmed by Actinomycin D inhibition assay and luciferase reporter assay. Furthermore, ChIRP-seq and ChIP-seq showed that LINC02273 stimulated oncogene AGR2 expression by directly binding to the AGR2 promoter region and increasing H3K27ac modification. Triplex formation assay was performed for verification. We demonstrated that the expression level and oncogenic ability of AGR2 were regulated by hnRNPL through LINC02273. Clinical data and mouse xenograft tumors also revealed the positive correlation of AGR2 and LINC02273. In conclusion, LINC02273, which is stabilized by hnRNPL can promote breast cancer metastasis through upregulation of AGR2 and may serve as a prognostic biomarker for breast cancer.
Citation Format: Xiu B, Chi Y, Ji W, Zhang Q, Wu J. LINC02273 interacts with hnRNPL and promotes metastasis through directly activating AGR2 in breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-05-08.
Abstract P6-09-06: BRCAness as a prognostic marker in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: A multicenter retrospective study
Authors: Kosaka Y , Yamamoto Y , Nishimiya H , Ibusuki-Yamamoto M , Hirota Y , Tanino H , Iwase H , Nakamura S , Akashi-Tanaka S 
Published: May 2019

Abstract
Background: Triple negative breast cancer (TNBC) has several subtypes. Identification of markers associated with recurrence and poor prognosis in TNBC patients is critically needed. BRCAness is a set of traits in which BRCA1 dysfunction, arising from gene mutation, methylation or deletion, results in DNA repair deficiency. In the present study we evaluated the clinical significance and prognosis of BRCAness in a multicenter retrospective study.
Methods: Ninety-four TNBC patients treated with neoadjuvant chemotherapy (NAC) were enrolled from three hospitals in Japan for this retrospective study. Of these patients, 86 (91.5%) were treated with anthracyclines and taxanes. BRCAness was determined from 94 core needle biopsy (CNB) specimens prior to NAC and 50 surgical specimens without pathological complete response (pCR). The samples were assessed using multiplex ligation-dependent probe amplification (MLPA) and the amplicons were scored. Samples with scores &gt;0.5 were defined as having BRCAness.
Results: Of the 94 TNBC patients, 51 (54.3%) had BRCAness in CNB specimens. There were no significant differences in pCR rate or recurrence between the BRCAness and non-BRCAness groups. Among surgical specimens, the BRCAness group (19/50, 38%) had a significantly shorter recurrence-free survival (RFS) and disease-specific survival (DSS) compared with the non-BRCAness group (p &lt; 0.01 and p &lt; 0.05). The BRCAness group had independent prognostic factors for recurrence and survival in multivariate regression analysis.
Conclusions: The BRCAness of surgical specimens is a useful marker to predict prognosis in TNBC patients after NAC. A clinical trial to assess the clinical impact of platinum-containing drugs with BRCAness is planned.
Citation Format: Kosaka Y, Yamamoto Y, Nishimiya H, Ibusuki-Yamamoto M, Hirota Y, Tanino H, Iwase H, Nakamura S, Akashi-Tanaka S. BRCAness as a prognostic marker in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: A multicenter retrospective study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-09-06.
Abstract P6-09-07: Expression of miR-106b in circulating tumor cells is associated with EMT and prognosis in metastatic breast cancer patients
Authors: Tan W , Liang G , Xie X , Tan L , Sanders AJ , Liu Z , Ling Y , Zhong W , Jiang WG , Gong C 
Published: May 2019

Abstract
# Co-first author: W.T., G.L., X.X.
* Co-Correspondence: C.G. and W.G.J.
Abstract
Background: Circulating tumor cells (CTCs) display changes in epithelial-mesenchymal transition (EMT) markers and miRNAs regulate EMT in breast cancer cells. The association between EMT characteristics and miRNA expression in CTCs of metastatic breast cancer (MBC) patients and their clinical implications remain unknown.
Methods: CTC-specific miRNAs were screened based on comparison of the miRNA profile between CTC and primary tumor. RT-PCR was used to quantity the expression levels of EMT makers and miRNA candidates. We enrolled 219 MBC patients with CTCs ≥ 5/7.5mL blood from 2 cohorts and CTCs were detected and enriched by CellSearch. Overall survival (OS) and radiological response were analyzed. CTCs were divided into epithelial- (E-CTCs) and mesenchymal-like CTC (M-CTCs) phenotypes based on a cut-off value derived from suspended breast cancer cells recovered from PBMCs.
Results: MiR-106b displayed upregulation in CTCs, with a higher level in M-CTCs than E-CTCs. Patients with E-CTCs showed better OS than those with M-CTCs (HR 1.77, 95% CI 1.14-2.78, P =0.012). CTCs from chemo-resistant MBC patients exhibited higher miR-106b. CTC-specific miR-106b was negatively associated with therapy response and OS (HR 1.73, 95% CI 1.06-2.84, P = 0.029).
Conclusions: CTC-specific miR-106b was associated with EMT phenotypes of CTCs and may predict prognosis in MBC patients.
Citation Format: Tan W, Liang G, Xie X, Tan L, Sanders AJ, Liu Z, Ling Y, Zhong W, Jiang WG, Gong C. Expression of miR-106b in circulating tumor cells is associated with EMT and prognosis in metastatic breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-09-07.